Somnics
Somnics is a Taiwan-based medical device company (Taiwan OTC: 6633) that develops the iNAP Sleep Therapy System, a mask-free intraoral negative pressure device for treating obstructive sleep apnea, sold globally to the U.S. VA healthcare system, sleep clinics, and CPAP-intolerant patients across roughly a dozen countries.
- Company typePublic
- Founded2011
- HeadquartersHsinchu, Taiwan
- Headcount251–500
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Somnics does
Somnics Inc. (萊鎂醫療器材股份有限公司) is a Taiwan-based, Taiwan OTC-listed (stock code 6633) medical device company founded in 2011 that researches, develops, manufactures, and commercializes sleep therapy systems for obstructive sleep apnea (OSA). Its flagship iNAP Sleep Therapy System applies gentle intraoral negative pressure via a small mouth-console to stabilize the tongue, soft palate, and surrounding tissues, keeping the upper airway open during sleep without masks, hoses, belts, or forced air; the system is battery-powered, pocket-sized, and silent during operation. The product family includes iNAP One, iNAP Lite (NP-R03-K), ZEEBUD, iBreath, and the iNAP Lab+ companion app that streams sleep data to a cloud platform for clinician titration and remote monitoring.
Somnics generates revenue through sales of the iNAP console and recurring oral-interface consumables to healthcare institutions and patients; the June 2025 launch of iNAP Essentials — a $58/month, 24-month subscription bundling device, supplies, coaching, and app access — introduces a direct-to-consumer recurring model. Two adjacent revenue streams exist: Taiwan distribution of the Lucira Check It COVID-19 test kit through pharmacy chains at NT$1,890 per unit, and IVD contract manufacturing for Maxnerva Technology Services leveraging the company's ISO 7/Class 10,000 cleanroom.
The company goes to market through a hybrid model: enterprise and clinical marketing at respiratory and sleep conferences (ATS, ERS, DGSM, Sleep DownUnder), an exclusive U.S. federal channel via First Nation Group under Federal Supply Schedule contract #36F79719D0027 (already deployed in 36+ VA Medical Centers, targeting ~172 VA sleep centers), exclusive international distribution through LMT Korea in South Korea, retail pharmacy networks in Taiwan, and now a U.S. direct-to-consumer subscription channel. Regulatory clearances include FDA 510(k) (K193460, May 2020), EU CE Mark under MDD 93/42/EEC, Taiwan TFDA, Australia TGA, Hong Kong MDCO, Israel MOH, Malaysia MDA, Singapore HSA, Thailand TFDA MDCD, Vietnam DMEHW, and South Korea MFDS GMP. The company's IP portfolio (162 granted patents and 30 registered trademarks as of 2021) covers the negative pressure mechanism across the U.S., EU, Japan, Korea, China, Australia, and Southeast Asia.
Somnics firmographics
Firmographics- Name
- Somnics
- Legal name
- 萊鎂醫療器材股份有限公司
- Website
- https://somnics.com
- Company type
- Public
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Somnics is a Taiwan-based medical device company (Taiwan OTC: 6633) that develops the iNAP Sleep Therapy System, a mask-free intraoral negative pressure device for treating obstructive sleep apnea, sold globally to the U.S. VA healthcare system, sleep clinics, and CPAP-intolerant patients across roughly a dozen countries.
- Ownership category
- akta.pro rank
Somnics industry classification
Industry- Product category
- Sleep Apnea Therapy Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Sleep Apnea Therapy Devices (CPAP/APAP/BiPAP/ASV) (HLAHAGAA)
- akta.pro secondary industries
- Respiratory & Sleep RPM (COPD, asthma, sleep apnea) (HLALAFAB), Home Respiratory & Sleep Therapy Providers (DME-Integrated) (HLAFAEAF)
Keywords
Where Somnics is headquartered
LocationHeadquarters
- HQ city
- Hsinchu
- HQ country
- Taiwan
- HQ region
- Asia
Offices2 records
Markets served
Somnics business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- iNAP Sleep Therapy System (device + consumables): Sale of the iNAP console and oral interface consumables to patients and healthcare institutions. Revenue from device sales and repeat consumable purchases (e.g., oral interface accessories).
- iNAP Essentials Subscription Program: Monthly subscription at $58/month over 24 months, including full starter kit, supplies, coaching, and app integration — a recurring revenue model bundled with the device and support services.
- Lucira COVID-19 Test Kit Distribution: Distribution of Lucira Check It COVID-19 Test Kit in Taiwan at NT$1,890 per unit, generating one-time transaction revenue through pharmacy and retail channels.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | iNAP Essentials subscription covering device, consumables, coaching, and app — $58/month over 24 months |
| Unit Pricing | Pay-as-you-go | Lucira Check It COVID-19 Test Kit at NT$1,890 per unit (one-time purchase) |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels4 records
Somnics product offering
Product offeringCore offering
Somnics researches, develops, manufactures, and commercializes the iNAP Sleep Therapy System — a battery-powered intraoral negative pressure medical device that treats Obstructive Sleep Apnea (OSA) by stabilizing the tongue and soft palate through gentle oral suction, allowing natural nasal breathing without masks, hoses, or surgery. The portfolio spans iNAP One and iNAP Lite hardware variants, ZEEBUD and iBreath sub-brand products, the iNAP Lab+ cloud-monitoring companion app, and an iNAP Essentials subscription program for U.S. patients. The company also distributes the Lucira Check It COVID-19 Test Kit in Taiwan through pharmacy and retail channels.
Product overview
Somnics offers a portfolio of medical devices for treating Obstructive Sleep Apnea (OSA) centered on the iNAP Sleep Therapy System, which uses innovative negative pressure technology to maintain airway patency during sleep. The core iNAP platform includes multiple models (iNAP One, iNAP Lite) and is complemented by companion products ZEEBUD and iBreath. The ecosystem includes the iNAP Lab+ app for patient monitoring and the iNAP Essentials subscription program for affordable access. Somnics also distributed the Lucira COVID-19 nucleic acid test kit (萊析樂) in Taiwan as a separate product line.
Differentiator
Problem solved
Functional benefit
Brands
- iNAP: iNAP Sleep Therapy System - negative pressure device for treating Obstructive Sleep Apnea (OSA). Features include natural breathing through nose, mask-free operation, compact portable design, and quiet operation.
- ZEEBUD
- iBreath
Products and services
- iNAP Sleep Therapy System A battery-powered intraoral negative pressure medical device for treating Obstructive Sleep Apnea (OSA). It uses gentle suction to pull the tongue, soft palate, and surrounding soft tissues forward to maintain airway patency during sleep, enabling natural nasal breathing without masks, hoses, or forced air. Sold to VA Medical Centers, sleep clinics, and ENT physicians globally.
- iNAP One Sleep Therapy System An advanced version of the iNAP system offering precision therapy for OSA, available in multiple oral interface sizes with thermal-memory material and iNAP Lab+ app compatibility for cloud-based sleep monitoring. FDA 510(k)-cleared and listed on the U.S. Federal Supply Schedule for the VA healthcare system.
- iNAP Lite (NP-R03-K) A compact variant of the iNAP Sleep Therapy System, with Taiwan TFDA and Hong Kong registration, intended for treating Obstructive Sleep Apnea.
- ZEEBUD A product in Somnics' sleep therapy portfolio, sold under the ZEEBUD sub-brand. Specific product details are limited in the source materials.
- iBreath A product in Somnics' portfolio sold under the iBreath sub-brand. Specific product details are limited in the source materials.
- iNAP Essentials Subscription Program A monthly subscription program ($58/month over 24 months) that delivers the iNAP Sleep Therapy System directly to U.S. consumers, bundling a full starter kit, ongoing supplies, coaching, and iNAP Lab+ app integration to improve affordability and access to mask-free OSA therapy.
- Lucira Check It COVID-19 Test Kit (Taiwan distribution) Distribution of the Lucira Check It COVID-19 Test Kit (RT-LAMP molecular amplification technology, FDA EUA authorized) in Taiwan at NT$1,890 per unit through pharmacy and retail chains (Da Shu, Ding Ding, Quanbao, Heping, Xinpu, and PX Mart).
Quantifiable outcome
- Adjustable intraoral negative pressure therapy significantly improves treatment success rates and sleep quality for OSA patients (Sleep and Breathing journal, 2021)
- +1 more outcomes
Companies that use Somnics
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
Somnics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Somnics partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered minor and core.
- Lucira Health, Inc.minorTaiwan regional distributor for Lucira Check It COVID-19 Test Kit (RT-LAMP molecular amplification technology, FDA EUA authorized). Lucira granted Somnics exclusive overseas distribution rights. Product sold at NT$1,890 per unit through pharmacies and retail chains in Taiwan.
- 雲智匯科技服務 (Maxnerva Technology Services)minorStrategic partnership where Somnics provides IVD product engineering development and professional manufacturing services to Maxnerva, leveraging Somnics' QMS, ISO 7/Class 10,000 cleanroom, and medical device manufacturing expertise. Expands Somnics' production capacity and capabilities into IVD contract manufacturing.
- First Nation GroupcoreExclusive partnership for U.S. federal healthcare (VA system) distribution of iNAP One via Federal Supply Schedule (Contract #36F79719D0027). First Nation Group provides remote setup and patient support services. Enables procurement across the VA healthcare system, covering 36+ existing VA Medical Centers and expansion to nearly 172 VA sleep centers.
- LMT Korea Co., LtdcoreExclusive South Korean distributor for iNAP. LMT Korea is the largest CPAP provider in South Korea, operating LÖWENSTEIN Academy (sleep training center) and serving over 200 medical institutions. Somnics obtained MFDS GMP certification in 2021, and product registration expected in Q3 2021. Partnership targets the estimated 1 in 5 South Koreans affected by OSA.
- 國立中央大學 (National Central University) — Prof. Lo Meng-zong and Prof. Lin ChengminorCo-development of the remote multi-physiological analysis platform system with National Central University. The cloud platform provides remote medical care services, combining Somnics' patented negative pressure sleep therapy device with cloud-based physiological data analysis. Won the 2020 Medication Technology R&D Bronze Award.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Somnics competitors and assessment
Company assessmentBroad incumbents
- ResMed: Global leader in CPAP and OSA therapy devices with multi-billion-dollar revenue, extensive physician relationships, and deep payer reimbursement infrastructure. Direct competitor in the OSA therapy market but serves as the entrenched standard-of-care that iNAP positions against as a mask-free alternative.
- Philips Respironics: Major incumbent in CPAP, BiPAP, and OSA therapy devices with broad hospital and homecare distribution. Despite recent CPAP recall challenges, remains one of the largest OSA therapy device providers globally and a key competitive benchmark for Somnics' market entry.
- Fisher & Paykel Healthcare: New Zealand-based manufacturer of CPAP devices, humidifiers, and respiratory care products with strong presence in OSA and hospital respiratory markets. Competes in the same sleep apnea therapy category with a broader respiratory portfolio.
Direct peers
- Inspire Medical Systems: Developer of an implantable hypoglossal nerve stimulation system for OSA as a CPAP alternative. Most directly comparable as an alternative OSA therapy targeting CPAP-intolerant patients with FDA-cleared, novel-mechanism devices. Listed on NYSE with established U.S. commercial infrastructure.
- BMC Medical: Chinese manufacturer of CPAP, BiPAP, and respiratory care devices with significant Asia-Pacific and emerging market distribution. Comparable to Somnics as an OSA device manufacturer targeting similar patient populations with mask-based positive pressure therapy.
- Apex Medical: Taiwanese medical device company manufacturing CPAP, BiPAP, and respiratory therapy products with strong Asia-Pacific presence. Closely comparable as a Taiwan-based OSA device peer competing in overlapping markets with similar hospital and homecare channels.
Emerging players
- Oventus Medical: Australian developer of oral appliance and novel airway devices for OSA treatment targeting CPAP-intolerant patients. Comparable as an emerging alternative OSA therapy company with a different mechanism (oral appliance) but similar patient segment and clinical positioning.
- Natus Medical: Provider of sleep diagnostics and neurological monitoring equipment used in sleep labs and home testing. Adjacent peer in the broader sleep medicine ecosystem with comparable clinical customers (sleep specialists, sleep centers) but focused on diagnostics rather than therapy.
- Itamar Medical: Israeli company (acquired by ZOLL Medical) developing home sleep apnea diagnostics and WatchPAT devices. Comparable as an Israel-based sleep medicine company with similar regulatory footprint and clinical focus on OSA diagnosis and management pathways.
Regional players
- Löwenstein Medical (LMT Korea partner): German respiratory and sleep therapy equipment manufacturer with established Korean distribution through LMT Korea (Somnics' exclusive Korean partner). Comparable as a CPAP and OSA therapy competitor with similar products in Somnics' distribution markets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Somnics social profiles
Digital presenceSomnics compliance and trust
Trust signalCompliance8 records
Somnics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Somnics leadership team
Management profileNumber of profiles
Profiles5 records
Somnics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Somnics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Somnics
What does Somnics do?
Somnics researches, develops, manufactures, and commercializes the iNAP Sleep Therapy System — a battery-powered intraoral negative pressure medical device that treats Obstructive Sleep Apnea (OSA) by stabilizing the tongue and soft palate through gentle oral suction, allowing natural nasal breathing without masks, hoses, or surgery. The portfolio spans iNAP One and iNAP Lite hardware variants, ZEEBUD and iBreath sub-brand products, the iNAP Lab+ cloud-monitoring companion app, and an iNAP Essentials subscription program for U.S. patients. The company also distributes the Lucira Check It COVID-19 Test Kit in Taiwan through pharmacy and retail channels.
Is Somnics a public or private company?
Somnics is a public company. It is classified as public and is currently operating.
When was Somnics founded?
Somnics was founded in 2011. It employs 251 to 500 people.
Where is Somnics based?
Somnics is headquartered in Hsinchu, Taiwan, in the Asia region.
How does Somnics make money?
Three revenue lines are on record. iNAP Sleep Therapy System (device + consumables) is the primary driver. The others are iNAP Essentials Subscription Program and lucira COVID-19 Test Kit Distribution.
Who are Somnics's main competitors?
Broad incumbents on record are ResMed, Philips Respironics and Fisher & Paykel Healthcare. Direct peers are Inspire Medical Systems, BMC Medical and Apex Medical. Emerging players are Oventus Medical, Natus Medical and Itamar Medical. Löwenstein Medical (LMT Korea partner) is listed as a regional player.
Does Somnics have an API?
No public API is recorded for Somnics.
What industry is Somnics in?
Somnics's product category is Sleep Apnea Therapy Medical Devices. Its primary akta.pro industry code is HLAHAGAA, Sleep Apnea Therapy Devices (CPAP/APAP/BiPAP/ASV), with a secondary code of HLALAFAB, Respiratory & Sleep RPM (COPD, asthma, sleep apnea). Its NAICS code is 334510 and its SIC code is 3841.